News

RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application

RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application   RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application – Hebrew

Read More...

RedHill Biopharma to Present at the 26th Annual ROTH Conference

RedHill Biopharma to Present at the 26th Annual ROTH Conference

Read More...

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property   RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property – Hebrew

Read More...

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film   RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film – Hebrew

Read More...

RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation

RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation   RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation – Hebrew

Read More...

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results   RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results – Hebrew

Read More...

RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines

RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines   RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines – Hebrew

Read More...

RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement

RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement   RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement – Hebrew

Read More...

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement   RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement – Hebrew

Read More...

RedHill Biopharma Announces Closing of $8.5 Million Private Placements from OrbiMed and Broadfin

Form 6-K RedHill Biopharma Announces Closing of $8.5 Million Private Placements from OrbiMed and Broadfin

Read More...

News